Elevated IL-10, IL-22, IL-24 and IL-26 in plasma samples of children with infectious mononucleosis
Abstract
Background: Infectious mononucleosis (IM) is an infectious disease with different stages of onset, and the pathogenesis of IM remains unclear. Objective: To investigate the levels of IL-10 family cytokines IL-10, IL-22, IL-24 and IL-26 in plasma samples of patients with infectious mononucleosis (IM), and the potential diagnostic values. Methods: Thirty children with IM were enrolled in the study and the plasma samples were collected, 30 healthy children served as the controls. Plasma samples from the patients and healthy controls were collected, and the expression levels of IL-10, IL-22, IL-24, IL-26, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have been determined by Elisa method. Moreover, the potential diagnostic value of IL-10, IL-22, IL-24 and IL-26 has been analyzed using ROC curve analysis, and the correlation between the levels of IL-10, IL-22, IL-24 and IL-26 in patients was analyzed. Finally, correlation between IL-10, IL-22, IL-24 and IL-26 and ALT as well as AST were analyzed. Results: The levels of IL-10, IL-22, IL-24 and IL-26 all increased in plasma samples of IM patients in comparison with healthy controls; ROC analysis showed that the AUC of IL-10, IL-22, IL-24 and IL-26 were 0.8500, 0.7078, 0.8056, and 0.9167, respectively, suggesting that IL-10, IL-22, IL-24 and IL-26 were good biomarkers; Moreover, the levels of IL-10, IL-22, IL-24 and IL-26 were positively correlated with the ALT and AST of the patients. Conclusions: IL-10, IL-22, IL-24 and IL-26 were upregulated in plasma of IM patients, suggesting that they may function as potential biomarkers.
Copyright (c) 2025 Jun Sun, Dalei Li, Kangwei Mao, Peiliang Luo, Ziqiang Zheng, Jiangyan Liu, Chenxi Zhang, Siyu Gu, Rui Zhang, Juan Wang

This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
